A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Official Title

An Open-Label, Multicentre, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Summary:

This is a Phase 1/1b dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Trial Description

Primary Outcome:

  • Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)
  • Percentage of Participants With Adverse Events
  • BTCT4465A (Mosunetuzumab) Serum Concentration
  • Atezolizumab Serum Concentration
  • Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHL
Secondary Outcome:
  • Duration of Response as Assessed Using Standard Criteria for NHL
  • Progression-Free Survival (PFS) as Assessed Using Standard Criteria for NHL
  • Overall Survival
  • European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Scores to Assess Health-Related Quality of Life (HRQoL)
  • Objective Response Rate (ORR)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society